CN109562133A - 难辨梭菌感染的治疗 - Google Patents

难辨梭菌感染的治疗 Download PDF

Info

Publication number
CN109562133A
CN109562133A CN201780049780.0A CN201780049780A CN109562133A CN 109562133 A CN109562133 A CN 109562133A CN 201780049780 A CN201780049780 A CN 201780049780A CN 109562133 A CN109562133 A CN 109562133A
Authority
CN
China
Prior art keywords
seq
composition
clostridium
bacterial strain
purifying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780049780.0A
Other languages
English (en)
Chinese (zh)
Inventor
J·施奈德
Y-G·金
B·奥利
S·雷迪
J·诺曼
J·巴塔罗尤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vedanta Biosciences Inc
Original Assignee
Vedanta Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vedanta Biosciences Inc filed Critical Vedanta Biosciences Inc
Publication of CN109562133A publication Critical patent/CN109562133A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201780049780.0A 2016-06-14 2017-06-14 难辨梭菌感染的治疗 Pending CN109562133A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662349914P 2016-06-14 2016-06-14
US62/349,914 2016-06-14
PCT/US2017/037498 WO2017218680A1 (en) 2016-06-14 2017-06-14 Treatment of clostridium difficile infection

Publications (1)

Publication Number Publication Date
CN109562133A true CN109562133A (zh) 2019-04-02

Family

ID=60664224

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780049780.0A Pending CN109562133A (zh) 2016-06-14 2017-06-14 难辨梭菌感染的治疗

Country Status (13)

Country Link
US (1) US12390498B2 (enExample)
EP (2) EP3468573B1 (enExample)
JP (3) JP7168558B2 (enExample)
KR (4) KR102554351B1 (enExample)
CN (1) CN109562133A (enExample)
AU (2) AU2017285211B2 (enExample)
CA (2) CA3027917C (enExample)
DK (1) DK3468573T5 (enExample)
ES (1) ES2960053T3 (enExample)
FI (1) FI3468573T3 (enExample)
MX (2) MX2018015522A (enExample)
PT (1) PT3468573T (enExample)
WO (1) WO2017218680A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115515611A (zh) * 2019-08-15 2022-12-23 百奥利康微生物有限公司 用于治疗疾病的细菌组合物
CN115867146A (zh) * 2020-02-07 2023-03-28 杜邦营养生物科学有限公司 用于动物健康的饲料组合物
CN117797176A (zh) * 2024-03-01 2024-04-02 南京大学 双胞梭菌在制备治疗非酒精性脂肪性肝病药物中的应用和一种药物

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102554351B1 (ko) 2016-06-14 2023-07-13 베단타 바이오사이언시즈, 인크. 클로스트리디움 디피실레 감염의 치료
EP3606325B1 (en) 2017-04-03 2024-09-04 Gusto Global, LLC Rational design of microbial-based biotherapeutics
EP3703720A1 (en) 2017-10-30 2020-09-09 Seres Therapeutics, Inc. Compositions and methods for treating antibiotic resistance
AU2018365071B2 (en) * 2017-11-09 2025-09-11 Vedanta Biosciences, Inc. Compositions and methods for the treatment of allergy
EP3723776A4 (en) 2017-12-11 2022-07-27 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms
KR20200138333A (ko) * 2018-03-29 2020-12-09 세레스 테라퓨틱스, 인코포레이티드 염증성 장 질환을 치료하는 조성물 및 방법
SG11202012621VA (en) * 2018-06-19 2021-01-28 4D Pharma Res Ltd Dosage form comprising a live biotherapeutic product
IL280779B2 (en) * 2018-08-17 2025-05-01 Vedanta Biosciences Inc Compositions for use in the treatment or prevention of Clostridium difficile infection
IL265735A (en) 2019-03-31 2019-05-30 Biomica A microbial consortium and its uses
WO2021011887A1 (en) * 2019-07-17 2021-01-21 University Of Utah Research Foundation Clostridia consortia compositions and methods of treating obesity, metabolic syndrome and irritable bowel disease
EP3858363A1 (en) 2020-01-28 2021-08-04 Institut national de recherche pour l'agriculture, l'alimentation et l'environnement Composition for treating intestinal or pulmonary diseases
GB202007452D0 (en) * 2020-05-19 2020-07-01 Microbiotica Ltd Threrapeutic bacterial composition
WO2022039561A1 (ko) * 2020-08-21 2022-02-24 서울대학교산학협력단 클로스트리디움 디피실리 감염의 치료 또는 예방용 조성물
KR102296288B1 (ko) * 2020-12-31 2021-09-01 주식회사 바이오뱅크힐링 락토바실러스 루테리 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102269966B1 (ko) * 2021-01-12 2021-06-28 주식회사 바이오뱅크힐링 루미노코쿠스 파에시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN117241809A (zh) 2021-01-21 2023-12-15 韦丹塔生物科学股份有限公司 用于治疗肝性脑病的组合物和方法
EP4294413A1 (en) * 2021-02-18 2023-12-27 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms
US20240226191A1 (en) * 2021-05-10 2024-07-11 Microba Ip Pty Ltd Compositions and methods for treating disease
KR102351145B1 (ko) * 2021-08-02 2022-01-14 주식회사 바이오뱅크힐링 비피도박테리움 롱검 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102331484B1 (ko) * 2021-08-02 2021-12-01 주식회사 바이오뱅크힐링 블라우티아 마실리엔시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102351146B1 (ko) * 2021-08-02 2022-01-14 주식회사 바이오뱅크힐링 페디오코쿠스 에시디락티시 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2023014054A1 (ko) * 2021-08-02 2023-02-09 주식회사 바이오뱅크힐링 블라우티아 속 균주, 류코노스톡 속 균주 또는 루미노코쿠스 속 균주 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102351147B1 (ko) * 2021-08-02 2022-01-14 주식회사 바이오뱅크힐링 블라우티아 오베움 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102351148B1 (ko) * 2021-08-02 2022-01-14 주식회사 바이오뱅크힐링 페디오코쿠스 펜토사세우스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102331486B1 (ko) * 2021-08-02 2021-12-01 주식회사 바이오뱅크힐링 비피도박테리움 슈도카테눌라튬 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102331485B1 (ko) * 2021-08-02 2021-12-01 주식회사 바이오뱅크힐링 블라우티아 웩슬러래 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102331483B1 (ko) * 2021-08-02 2021-12-01 주식회사 바이오뱅크힐링 류코노스톡 락티스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2023014048A1 (ko) * 2021-08-02 2023-02-09 주식회사 바이오뱅크힐링 비피도박테리움 속 균주 또는 페디오코쿠스 속 균주 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102792000B1 (ko) * 2021-10-21 2025-04-08 경북대학교 산학협력단 신규한 락토바실러스 루테리 psc102 균주 및 이의 용도
WO2023075458A1 (ko) * 2021-10-27 2023-05-04 주식회사 바이오뱅크힐링 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102337995B1 (ko) * 2021-11-10 2021-12-14 주식회사 바이오뱅크힐링 아가토바쿨룸 부티리시프로두켄스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102337998B1 (ko) * 2021-11-03 2021-12-14 주식회사 바이오뱅크힐링 로제부리아 파에시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102365420B1 (ko) * 2022-01-04 2022-02-23 주식회사 바이오뱅크힐링 로제부리아 인테스티날리스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2023132628A1 (ko) * 2022-01-04 2023-07-13 주식회사 바이오뱅크힐링 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102444328B1 (ko) * 2022-03-11 2022-09-19 주식회사 바이오뱅크힐링 아나에로스티페스 하드루스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
US20250205261A1 (en) 2022-03-18 2025-06-26 Meiji Co., Ltd. Composition for controlling growth of bacteria in the intestinal tract and use thereof
KR102626400B1 (ko) * 2022-08-31 2024-01-19 주식회사 바이오뱅크힐링 도레아 론기카테나 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102620185B1 (ko) * 2023-08-08 2024-01-04 주식회사 바이오뱅크힐링 블라우티아 호미니스 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도
KR102620186B1 (ko) * 2023-08-08 2024-01-04 주식회사 바이오뱅크힐링 리모실락토바실러스 뮤코세 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도
KR102628942B1 (ko) * 2023-08-08 2024-01-26 주식회사 바이오뱅크힐링 레비락토바실러스 브레비스 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도
WO2025033636A1 (ko) * 2023-08-08 2025-02-13 주식회사 바이오뱅크힐링 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2025033635A1 (ko) * 2023-08-08 2025-02-13 주식회사 바이오뱅크힐링 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2025076184A1 (en) 2023-10-03 2025-04-10 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
WO2025093777A1 (en) 2023-11-05 2025-05-08 Human Biome Institute S.A. Functional compositions and methods of use thereof in the treatment and recurrence prophylaxis of clostridioides difficile infection and restoration of healthy microbiota

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014121301A1 (en) * 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
JP2015500792A (ja) * 2011-12-01 2015-01-08 国立大学法人 東京大学 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌
WO2015077794A1 (en) * 2013-11-25 2015-05-28 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2016086206A1 (en) * 2014-11-25 2016-06-02 Epiva Biosciences, Inc. Probiotic compositions containing clostridials for inhibiting inflammation

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205A (en) 1845-09-23 Spark-arrester
US132A (en) 1837-02-25 Improvement in propelling machinery by magnetism and electro-magnetism
US3261761A (en) 1962-05-07 1966-07-19 Arthur W Anderson Method of freeze drying bacterial cultures
ES2248822T3 (es) 1995-09-15 2006-03-16 Dale N. Gerding Procedimientos y composiciones para la prevencion y el tratamiento de enfermedades asociadas al clostridium difficile.
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20090197249A1 (en) 2004-11-01 2009-08-06 George Mason University Compositions and methods for diagnosing colon disorders
AU2006219475B8 (en) 2005-03-03 2013-02-07 Meiji Co., Ltd. Immune function modulating agents
US9603876B2 (en) 2008-09-25 2017-03-28 New York University Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment
GB0916335D0 (en) 2009-09-17 2009-10-28 Martin W J Medicaments
ES2916399T3 (es) 2010-02-01 2022-06-30 Rebiotix Inc Bacterioterapia para la colitis por Clostridium difficile
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
KR20130098320A (ko) 2010-08-04 2013-09-04 토마스 줄리어스 보로디 분변 세균총 이식을 위한 조성물, 그의 제조 방법과 사용 방법, 및 그를 전달하기 위한 장치
WO2012024638A2 (en) 2010-08-20 2012-02-23 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
WO2012098358A1 (en) 2011-01-20 2012-07-26 Biopharma Technology Ltd Freeze drying method
EP2713726A2 (en) 2011-05-23 2014-04-09 Washington State University Research Foundation Use of photosynthetic pigment stabilizing agents to regulate ripening and quality in fruits and vegetables
CA2848757C (en) 2011-09-14 2021-11-09 University Of Guelph Methods to culture human gastrointestinal microorganisms
CN104780932A (zh) 2012-02-29 2015-07-15 伊西康内外科公司 微生物区系的组合物及与其相关的方法
WO2013146319A1 (ja) 2012-03-30 2013-10-03 味の素株式会社 糖尿病誘起細菌
ES2792106T3 (es) 2012-05-18 2020-11-10 Genome Res Ltd Métodos y grupos
CN106620189B (zh) 2012-06-06 2021-11-19 上海交通大学 改善肠道菌群结构的方法及应用
WO2014029578A1 (en) 2012-08-24 2014-02-27 Haldor Topsøe A/S Method and catalyzed filter element with improved alkali-resistance for flue gas cleaning
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
NZ709392A (en) 2012-11-23 2016-10-28 Seres Therapeutics Inc Synergistic bacterial compositions and methods of production and use thereof
WO2014153194A2 (en) 2013-03-14 2014-09-25 Seres Health, Inc. Methods for pathogen detection and enrichment from materials and compositions
BR112015023124A2 (pt) 2013-03-14 2017-07-18 Therabiome Llc liberação de organismos probióticos e/ou agentes terapêuticos almejada para o trato gastrintestinal
WO2014150094A1 (en) 2013-03-15 2014-09-25 University Of Florida Research Foundation, Inc. Butyrogenic bacteria as probiotics to treat clostridium difficile
AU2014232370B2 (en) 2013-03-15 2018-11-01 Société des Produits Nestlé S.A. Network-based microbial compositions and methods
EP3019181A4 (en) 2013-07-09 2016-09-21 Puretech Ventures Llc COMPOSITIONS WITH COMBINATIONS OF BIOACTIVE MOLECULARS DERIVED FROM MICROBOTS FOR TREATING DISEASES
AU2014331610B2 (en) 2013-10-03 2019-11-07 Trustees Of The University Of Pennsylvania Compositions comprising a defined microbiome and methods of use thereof
WO2015095241A2 (en) 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
JP6617935B2 (ja) 2014-04-10 2019-12-11 国立研究開発法人理化学研究所 Ｔｈ１７細胞の誘導のための組成物及び方法
EP3134509A4 (en) 2014-04-23 2017-09-13 Cornell University Modulation of fat storage in a subject by altering population levels of christensenellaceae in the gi tract
US20170087196A1 (en) 2014-05-19 2017-03-30 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing clostridium difficile infection
EP4529950A3 (en) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
ES3010296T3 (en) 2014-11-25 2025-04-02 Memorial Sloan Kettering Cancer Center Intestinal microbiota and gvhd
KR102561989B1 (ko) 2015-05-14 2023-07-31 핀치 테라퓨틱스 홀딩스 엘엘씨 대변 균무리 이식용 조성물, 및 이의 제조 및 사용 방법, 및 이의 전달을 위한 장치
WO2016185469A1 (en) 2015-05-21 2016-11-24 Yeda Research And Development Co. Ltd. Bacterial populations for promoting health
US20180153944A1 (en) 2015-06-09 2018-06-07 Regents Of The University Of Minnesota Methods for detecting risk of having a bloodstream infection and compositions for reducing the risk
PL3240554T3 (pl) 2015-06-15 2020-02-28 4D Pharma Research Limited Blautia stercosis i wexlerae do stosowania w leczeniu chorób zapalnych i autoimmunologicznych
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
JP6426264B2 (ja) 2015-06-15 2018-11-21 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
RS59038B1 (sr) 2015-06-15 2019-08-30 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
JP2018519295A (ja) 2015-06-22 2018-07-19 プレジデント アンド フェローズ オブ ハーバード カレッジ 粘膜固有層調節性ｔ細胞の誘導
KR20180025908A (ko) 2015-07-08 2018-03-09 세레스 테라퓨틱스, 인코포레이티드 대장염의 치료 방법
JP7088827B2 (ja) 2015-08-24 2022-06-21 ニューバイヨタ エルエルシー 糞便由来細菌集団を使用する腸内毒素症の治療システム及び方法
CA3003138A1 (en) 2015-10-26 2017-05-04 Crestovo Holdings Llc Compositions and methods for fecal microbiota-related therapy
CA3005781C (en) 2015-11-20 2019-01-22 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MX2018006283A (es) 2015-11-24 2019-09-06 Seres Therapeutics Inc Composiciones bacterianas diseñadas.
HK1246670B (en) 2016-03-04 2020-05-15 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
US20170290889A1 (en) 2016-04-11 2017-10-12 New York University Methods and compositions for treating dysbiosis and gastrointestinal and inflammatory disorders
KR102554351B1 (ko) 2016-06-14 2023-07-13 베단타 바이오사이언시즈, 인크. 클로스트리디움 디피실레 감염의 치료
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
JP7516007B2 (ja) 2016-06-28 2024-07-16 セリバ・バイオロジクス・インコーポレイテッド 経口抗生物質からのマイクロバイオーム防御
WO2018080477A1 (en) 2016-10-26 2018-05-03 The Joan & Irwin Jacobs Technion-Cornell Institute Systems and methods for ultra-fast identification and abundance estimates of microorganisms using a kmer-depth based approach and privacy-preserving protocols
US20210196766A1 (en) 2018-05-24 2021-07-01 Seres Therapeutics, Inc. Designed bacterial compositions and uses thereof
IL280779B2 (en) 2018-08-17 2025-05-01 Vedanta Biosciences Inc Compositions for use in the treatment or prevention of Clostridium difficile infection
CN117241809A (zh) 2021-01-21 2023-12-15 韦丹塔生物科学股份有限公司 用于治疗肝性脑病的组合物和方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500792A (ja) * 2011-12-01 2015-01-08 国立大学法人 東京大学 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌
WO2014121301A1 (en) * 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
US20140328803A1 (en) * 2013-02-04 2014-11-06 Seres Health, Inc. Compositions and Methods
CN105451561A (zh) * 2013-02-04 2016-03-30 赛里斯治疗公司 组合物和方法
WO2015077794A1 (en) * 2013-11-25 2015-05-28 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2016086206A1 (en) * 2014-11-25 2016-06-02 Epiva Biosciences, Inc. Probiotic compositions containing clostridials for inhibiting inflammation

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
LAGKOUVARDOS I.等: ""[Clostridium] innocuum strain I46 16S ribosomal RNA gene, partial sequence"", 《GENBANK》 *
MIRJANA等: ""The first 1000 cultured species of the human gastrointestinal microbiota"", 《FEMS MICROBIOL REV》 *
NCBI: ""Blautia hansenii strain JCM 14655 16S ribosomal RNA gene, partial sequence"", 《GENBANK》 *
REETTA SATOKARI 等: ""Fecal Transplantation Treatment of Antibiotic-Induced, Noninfectious Colitis and Long-Term Microbiota Follow-Up"", 《CASE REPORTS IN MEDICINE》 *
ROSSI-TAMISIER等: ""Cautionary tale of using 16S rRNA gene sequence similarity values in identification of human-associated bacterial species"", 《INT J SYST EVOL MICROBIOL》 *
SAKAMOTO M.等: ""[Clostridium] symbiosum gene for 16S ribosomal RNA, partial sequence, strain: JCM 1297"", 《GENBANK》 *
SEIKO NARUSHIMA等: ""Characterization of the 17 strains of regulatory T cell inducing human derived Clostridia"", 《GUT MICROBES》 *
STACKEBRANDT等: ""Phylogenetic basis for a taxonomic dissection of the genus Clostridium"", 《FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY》 *
THAPA DINESH等: ""Essential oils have different effects on human pathogenic and commensal bacteria in mixed faecal fermentations compared with pure cultures"", 《MICROBIOLOGY-SGM》 *
VANNI BUCCI等: ""MDSINE: Microbial Dynamical Systems INference Engine for microbiome time-series analyses"", 《GENOME BIOLOGY》 *
俞守义等: "《现代热带医学（上册）》", 31 August 2012, 军事医学科学出版社 *
姚咏明等: "《脓毒症防治学》", 31 January 2008 *
张发明等: ""粪菌移植的概念、历史、现状和未来"", 《中国内镜杂志》 *
苏德模等: "《药品微生物学检验技术》", 31 January 2007, 华龄出版社 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115515611A (zh) * 2019-08-15 2022-12-23 百奥利康微生物有限公司 用于治疗疾病的细菌组合物
CN115867146A (zh) * 2020-02-07 2023-03-28 杜邦营养生物科学有限公司 用于动物健康的饲料组合物
CN115867146B (zh) * 2020-02-07 2025-01-17 国际N&H丹麦有限公司 用于动物健康的饲料组合物
CN117797176A (zh) * 2024-03-01 2024-04-02 南京大学 双胞梭菌在制备治疗非酒精性脂肪性肝病药物中的应用和一种药物

Also Published As

Publication number Publication date
KR102862927B1 (ko) 2025-09-23
KR102554351B1 (ko) 2023-07-13
MX2018015522A (es) 2019-07-12
JP7168558B2 (ja) 2022-11-09
FI3468573T3 (fi) 2023-10-02
US20240123000A1 (en) 2024-04-18
MX2023003461A (es) 2023-04-19
JP7483828B2 (ja) 2024-05-15
ES2960053T3 (es) 2024-02-29
KR20250140643A (ko) 2025-09-25
KR20230107416A (ko) 2023-07-14
JP2019517828A (ja) 2019-06-27
KR20190030687A (ko) 2019-03-22
EP3468573A4 (en) 2020-03-04
WO2017218680A1 (en) 2017-12-21
AU2017285211B2 (en) 2024-06-27
EP4282489A3 (en) 2024-01-10
EP3468573A1 (en) 2019-04-17
CA3027917C (en) 2024-02-20
DK3468573T3 (da) 2023-10-16
CA3027917A1 (en) 2017-12-21
DK3468573T5 (da) 2024-09-09
AU2024216443A1 (en) 2024-09-19
JP2023017845A (ja) 2023-02-07
PT3468573T (pt) 2023-10-16
US12390498B2 (en) 2025-08-19
KR20240055124A (ko) 2024-04-26
EP4282489A2 (en) 2023-11-29
KR102658297B1 (ko) 2024-04-18
EP3468573B1 (en) 2023-08-09
JP2024109615A (ja) 2024-08-14
AU2017285211A1 (en) 2019-01-24
CA3226196A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
CN109562133A (zh) 难辨梭菌感染的治疗
US11701396B2 (en) Treatment of Clostridium difficile infection
Leahy et al. Getting better with bifidobacteria
KR20200136365A (ko) 공동선택 미생물총을 포함하는 조성물 및 그 이용 방법
Holzapfel Introduction to prebiotics and probiotics
AU2017327485B2 (en) Bacteria
Paliy et al. Specific composition of indigenous microflora (Lactobacillus spp., Bifidobacterium spp., Lactococcus spp.) in farm animals
Li et al. A newly isolated E. thailandicus strain d5B with exclusively antimicrobial activity against C. difficile might be a novel therapy for controlling CDI
Yavuzdurmaz Isolation, characterization, determination of probiotic properties of lactic acid bacteria from human milk
WO2014064488A1 (en) Streptococcus thermophilus strains for treating helicobacter pylori infection
Adam et al. Probiotics: Recent understandings and biomedical applications
US20230022942A1 (en) Method for analyzing ileostomy subjects using a probiotic containing bacillus subtilis
HK40104391A (en) Treatment of clostridium difficile infection
Kalkan et al. in Terms of the Food Safety and Human
Gibson et al. Final technical report for FSA project Ref G01022
Class et al. Patent application title: Strain of L. Bulgaricus Capable of Inhibiting the Adhesion of H. Pylori Strains to Epithelial Cells Inventors: Peggy Garault (Montlhery, FR) Peggy Garault (Montlhery, FR) Gaëlle Quere (Villebon Sur Yvette, FR) Raphaëlle Bourdet-Sicard (Palaiseau, FR) Raphaëlle Bourdet-Sicard (Palaiseau, FR) Raphaëlle Bourdet-Sicard (Palaiseau, FR) Francis Megraud (Bordeaux, FR) Assignees: COMPAGNIE GERVAIS DANONE

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination